Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK4 | Q13043 | 7/20 | 0.45 |
| ▸ | STK3 | Q13188 | 7/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30295902 | 0.89 | STK4 (0.44) | STK4STK3LRRK2LMNATP53 | |
| SCHEMBL30295809 | 0.88 | LMNA (0.46) | STK4STK3LRRK2LMNATP53 | |
| SCHEMBL30295816 | 0.86 | LMNA (0.47) | STK4STK3LRRK2LMNATP53 | |
| SCHEMBL30296050 | 0.86 | LRRK2 (0.62) | STK4STK3LRRK2LMNATP53 | |
| SCHEMBL30295744 | 0.82 | STK4 (0.41) | STK4STK3LRRK2LMNATP53 | |
| SCHEMBL30295700 | 0.82 | SRC (0.42) | STK4STK3LRRK2LMNATP53 | |
| SCHEMBL31301627 | 0.80 | STK4 (0.46) | STK4STK3LRRK2LMNATP53 | |
| SCHEMBL30295781 | 0.80 | STK4 (0.46) | STK4STK3LRRK2LMNATP53 | |
| SCHEMBL31301618 | 0.79 | RIPK2 (0.39) | STK4STK3LRRK2LMNATP53 | |
| SCHEMBL30295769 | 0.77 | STK4 (0.53) | STK4STK3LRRK2LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051337-A1 | INHIBITORS OF SERINE/THREONINE PROTEIN KINASE STK3 OR STK4 AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2025-02-13 | — | — | US | disclosed |
| WO-2023055731-A1 | INHIBITORS OF SERINE/THREONINE PROTEIN KINASE STK3 OR STK4 AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051337-A1 | INHIBITORS OF SERINE/THREONINE PROTEIN KINASE STK3 OR STK4 AND USES THEREOF | STK3, STK4, STK36 | STK4 2/4885STK3 1/4885LRRK2 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.